<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="">
    <meta name="author" content="">
    <title>Project  &raquo; Aid on Spreadsheets</title>
    <link href="/static/vendor/bootstrap-3.2.0/css/bootstrap.min.css" media="all" rel="stylesheet" type="text/css" />
    <script src="/static/vendor/jquery/3.2.1/jquery-3.2.1.min.js" type="text/javascript"></script>
    <script src="/static/vendor/bootstrap-3.2.0/js/bootstrap.js" type="text/javascript"></script>
    <script src="/static/vendor/jquery.tablesorter.min.js" type="text/javascript"></script>
    <link href="/static/style.css" media="all" rel="stylesheet" type="text/css" />
</head>
<body>
    <div class="navbar navbar-static-top">
      <div class="navbar-inner">
        <div class="container-fluid header-container">
          <a class="btn btn-navbar" data-toggle="collapse" data-target=".nav-collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <h1 class="brand"><a href="/en/">Aid on Spreadsheets</a>
          </h1>
        </div>
      </div>
    </div>
    
    <nav class="navbar navbar-country" role="navigation">
      <div class="container-fluid">
        <!-- Brand and toggle get grouped for better mobile display -->
        <div class="navbar-header">
          <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1">
            <span class="sr-only">Toggle navigation</span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </button>
          <a class="navbar-brand" href="/en/countries/UG/">Uganda</a>
        </div>

        <!-- Collect the nav links, forms, and other content for toggling -->
        <div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1">
          <ul class="nav navbar-nav">
            <li >
              <a href="/en/countries/UG/">
                Overview
                <span class="sr-only">(current)</span>
              </a>
            </li>
            <li >
              <a href="/en/countries/UG/activities/">
                Projects
              </a>
            </li>
            
          </ul>
          <ul class="nav navbar-nav navbar-right">
          <li>
            <a href="/en/countries/UG/activities/SE-0-SE-29-2015-03295_1-285-12182/">EN</a>
          </li>
          <li>
            <a href="/fr/countries/UG/activities/SE-0-SE-29-2015-03295_1-285-12182/">FR</a>
          </li>
          
          </ul>
        </div><!-- /.navbar-collapse -->
      </div><!-- /.container-fluid -->
    </nav>
    

  <div class="container-fluid body-container">
    
      
    
        
<br />


<h2>Randomized clinical trial to identify optimal pediatric efavirenz dosage to treat HIV infected infant and children in Africa</h2>


<p>More than 90% of the estimated 3.3 million HIV infected children worldwide live in Sub Saharan Africa. Efavirenz (EFV) is approved recently by US-FDA and WHO as part of first line combination ART for HIV infected children &gt;3 years of age. Based on results from few clinical studies, the US-FDA approved the use of EFV in infant and children aged ≥3 months weighing &gt;3.5 kg. Due to lack of efficacy, safety and pharmacokinetic data WHO continues to limit the use of EFV in children under &lt;3 years of age. 
The current body weight-based EFV dose recommended (FDA and WHO) to treat HIV in infant and children is scaled-down prediction from population pharmacokinetic modeling of data obtained from adult subjects treated with the standard maximum EFV dose. Biochemical and physiological processes between children and adults such as metabolism are disproportionate to their body weight differences. Although adult data is helpful to decide a first-in-children dose to initiate a safety, efficacy and PK study, the appropriate way to determine pharmacokinetic and pharmacodynamic parameters in children for a given age group is to conduct a dose optimization studies in specific age groups. 
Our extensive EFV dose optimization studies in Sub Saharan Africa patients indicate the importance of pharmacogenetic variations for efavirenz plasma exposure and treatment outcome. Based on population PK modeling of observational data, we demonstrated that standard 600 mg daily adult dose is unnecessarily high and recommended a dose reduction to 400 mg daily for adults in black African populations, which is confirmed by recent randomized clinical trials. In the present study we aim to perform a similar EFV dose optimization study specific for pediatrics population in Africa. EFV crosses the blood brain barrier and high plasma EFV concentration is associated with CNS toxicity, which may result in untoward effect for the developing child brain.
We hypothesize that with the current recommended EFV dose, the risk of under- or overdosing of EFV is eminent among black African children who exhibit significant nutritional, comorbidity and host-genetic diversity from populations where pharmacokinetic and safety studies are performed and data extrapolated with “one-dose-fit-all” principle. We aim to identify safe and effective efavirenz dosage recommendations specific for pediatric use to treat HIV infected infants and children in Sub Saharan Africa. A three-phase extensive efavirenz pharmacokinetics, pharmacogenetics and pharmacodynamics based EFV dose optimization study will be conducted in HIV and HIV-TB co-infected infant and children from two genetically diverse African populations (Uganda and Ethiopia) during 2016 – 2020.
First (Phase-1): observational study will be conducted to evaluate EFV plasma exposure, safety (skin rash, liver and CNS toxicity) and efficacy (immunologic and virological outcomes) of EFV based ART using the current EFV dose approved by FDA (&lt; 3 years of age) and WHO (&gt; 3 years of age) treatment guidelines. Patients will be enrolled prospectively and followed for one year. Application and feasibility of bedside genotype testing for patient care to aid EFV dose adjustment in HIV pediatric clinic will be developed and evaluated.
Secondly (Phase-2): Population pharmacokinetic, pharmacogenetic and pharmacodynamics modeling and simulation of the data we will be performed to identify the normal efavirenz therapeutic range and optimal predictive EFV dose recommendation for the various age group.
Thirdly (Phase-3): In a randomized clinical trial, we will evaluate the safety and efficacy of the predicted optimal EFV dose and compare it against the current FDA/WHO approved EFV dose recommendations. 
The study, to be conducted through a well-established multidisciplinary collaboration, will provide evidence-based recommendation for policy makers to develop safe and effective HIV treatment guidelines for the most vulnerable pediatric population in</p>

<dl class="dl-horizontal">
  <dt>Project ID</dt>
  <dd><code>SE-0-SE-29-2015-03295_1-285-12182</code></dd>
  <dt>Activity status</dt>
  <dd>2 - Implementation</dd>
  <dt>Aid type</dt>
  <dd>D02 - Other technical assistance</dd>
  <dt>% to Uganda</dt>
  <dd>100.00</dd>
</dl>

<h2>Organisations</h2>
<dl class="dl-horizontal">
  
  <dt>Funding</dt><dd>Sweden</dd>
  
  <dt>Extending</dt><dd>The Swedish Research Council</dd>
  
  <dt>Implementing</dt><dd>Karolinska Institutet</dd>
  
</dl>

<div class="modal" id="addSectorsModal" tabindex="-1" role="dialog" aria-labelledby="addSectorsModalLabel" aria-hidden="true">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <button type="button" class="close" data-dismiss="modal"><span aria-hidden="true">&times;</span><span class="sr-only">Close</span></button>
        <h4 class="modal-title">Add Sector</h4>
      </div>
      <div class="modal-body">
        <form class="form-horizontal" role="form">
          <div class="form-group">
            <label for="sector" class="col-sm-2 control-label">Sector</label>
            <div class="col-sm-10">
              <select class="form-control" id="sector-selector" name="sector">
                <option>Select one...</option>
                
              </select>
            </div>
          </div>
          <div class="form-group">
            <label for="sector-percentage" class="col-sm-2 control-label">Percentage</label>
            <div class="col-sm-10">
              <input type="text" class="form-control" id="sector-percentage" placeholder="Percentage">
            </div>
          </div>
        </form>
      </div>
      <div class="modal-footer">
        <button type="button" class="btn btn-default" data-dismiss="modal">Close</button>
        <button type="button" class="btn btn-primary btn-sector-add">Add</button>
      </div>
    </div><!-- /.modal-content -->
  </div><!-- /.modal-dialog -->
</div><!-- /.modal -->


<!--
<div class="pull-right">
  <a class="btn btn-success btn-lg" data-toggle="modal" data-target="#addSectorsModal" href="#addSectorsModal">
    <b>Add sector</b>
  </a>
</div>
-->
<div class="row">
  <div class="col-md-4">
    <h2>Disbursements by fiscal year, quarter </h2>

    <table class="table" id="sectors">
      <thead>
        <th>Fiscal year</th>
        <th>Fiscal quarter</th>
        <th>Value (USD)</th>
        <th>Uganda Value (USD)</th>
      </thead>
      <tbody>
    
        <tr>
          <td>2017</td>
          <td>Q2</td>
          <td>63,472.56</td>
          <td>63,472.56</td>
        </tr>
    
        <tr>
          <td>2016</td>
          <td>Q2</td>
          <td>63,402.09</td>
          <td>63,402.09</td>
        </tr>
    
      </tbody>
    </table>
  </div>
  <div class="col-md-4">
    <h2>Commitments by fiscal year, quarter </h2>
    <table class="table" id="sectors">
      <thead>
        <th>Fiscal year</th>
        <th>Fiscal quarter</th>
        <th>Value (USD)</th>
        <th>Uganda Value (USD)</th>
      </thead>
      <tbody>
    
        <tr>
          <td>2015</td>
          <td>Q3</td>
          <td>253,608.37</td>
          <td>253,608.37</td>
        </tr>
    
      </tbody>
    </table>
  </div>
  <div class="col-md-4">
    <h2>MTEF projections by fiscal year </h2>
    <table class="table" id="sectors">
      <thead>
        <th>Fiscal year</th>
        <th>Value (USD)</th>
        <th>Uganda Value (USD)</th>
      </thead>
      <tbody>
    
      </tbody>
    </table>
  </div>
</div>

<h2></h2>
<table class="table" id="sectors">
  <thead>
    <th>CRS code</th>
    <th>%</th>
  </thead>
  <tbody>
    
    <tr id="sector-12182">
      <td>
        Medical research
        (12182)
      </td>
      <td>
        100.0
      </td>
    </tr>
    
  </tbody>
</table>

  </div>
    <script type="text/javascript">
        $('.flashmessage').fadeIn('slow');
    </script>
    <footer class="footer">
    <div class="container">
    <div class="pull-left">
        <p><a href="https://github.com/markbrough/flatiati">Source code on Github</a>, released under the <a href="http://www.gnu.org/licenses/agpl-3.0.html">AGPL v3.0 License</a>.</p>
        <p><a href="http://aidtransparency.net">International Aid Transparency Initiative (IATI)</a></p>
        <p><a href="http://iatiregistry.org">IATI Registry</a> &ndash; <a href="http://iatistandard.org">IATI Standard</a></p>
    </div>
    <div class="pull-right">
        <p><a href="http://twitter.com/mark_brough">@mark_brough</a></p>
    </div>
    </div></footer>
</body>
</html>